{"DataElement":{"publicId":"2682630","version":"5","preferredName":"Acute Myeloid Leukemia Classification Type","preferredDefinition":"A description of acute myeloid leukemia classification.","longName":"2682625v1.00:2682512v2.10","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2682625","version":"1","preferredName":"Acute Myeloid Leukemia Classification","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001)_A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"AML_CLASS","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2320063","version":"1","preferredName":"Acute Myeloid Leukemia","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","longName":"C3171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-037A-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2321361","version":"1","preferredName":"Classification","preferredDefinition":"Classification; the grouping of things into classes or categories.","longName":"C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-20AF-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A58BC17-7018-71A5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-21","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-17","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2682512","version":"2.1","preferredName":"Acute Myeloid Leukemia Type","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001)._Something distinguishable as an identifiable class based on common qualities.","longName":"2682512v2.10","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Acute basophilic leukemia","valueDescription":"Acute Basophilic Leukemia","ValueMeaning":{"publicId":"2836779","version":"1","preferredName":"Acute Basophilic Leukemia","longName":"2836779","preferredDefinition":"A rare acute myeloid leukemia in which the immature cells differentiate towards basophils.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Basophilic Leukemia","conceptCode":"C3164","definition":"A rare acute myeloid leukemia in which the immature cells differentiate towards basophils.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-677E-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"COOPERM","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E6F9885-CB21-393C-E063-731AD00A98E1","beginDate":"2007-08-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2024-01-08","modifiedBy":"ONEDATA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with MLLT3::KMT2A fusion","valueDescription":null,"ValueMeaning":{"publicId":"3926632","version":"1","preferredName":"Acute Myeloid Leukemia with t(9;11)(p22.3;q23.3); MLLT3-KMT2A","longName":"3926632","preferredDefinition":"An acute myeloid leukemia associated with t(9;11)(p22.3;q23.3) and MLLT3-KMT2A fusion protein expression. Morphologically it usually has monocytic features. It may present at any age but it is more commonly seen in children. Patients may present with disseminated intravascular coagulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A","conceptCode":"C82403","definition":"An acute myeloid leukemia associated with t(9;11)(p21.3;q23.3) and MLLT3-KMT2A fusion protein expression. Morphologically it usually has monocytic features. It may present at any age but it is more commonly seen in children. Patients may present with disseminated intravascular coagulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E95A151A-B5AC-8777-E040-BB89AD433AA9","latestVersionIndicator":"Yes","beginDate":"2013-10-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CABD-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with other KMT2A rearrangements","valueDescription":null,"ValueMeaning":{"publicId":"7652770","version":"1","preferredName":"Acute Myeloid Leukemia with MLL Rearrangement","longName":"7652770","preferredDefinition":"An acute myeloid leukemia characterized by rearrangement of the MLL (mixed-lineage leukemia) gene. It affects infants, children and adults. It is usually associated with poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with KMT2A Rearrangement","conceptCode":"C174129","definition":"An acute myeloid leukemia characterized by rearrangement of the KMT2A gene. It affects infants, children and adults. It is usually associated with poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1FB1505-19EA-4113-E053-4EBD850AC42F","latestVersionIndicator":"Yes","beginDate":"2021-05-10","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-05-10","modifiedBy":"ONEDATA","dateModified":"2021-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CABE-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with DEK::NUP214 fusion","valueDescription":null,"ValueMeaning":{"publicId":"3257034","version":"1","preferredName":"Acute Myeloid Leukemia with t(6;9)(p23;q34.1); DEK-NUP214","longName":"3257034","preferredDefinition":"An acute myeloid leukemia associated with t(6;9)((p23;q34.1) resulting in DEK-NUP214(CAN) fusion protein expression. It is often associated with multilineage dysplasia and basophilia. It affects both children and adults and it usually has an unfavorable clinical outcome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with t(6;9)(p22.3;q34.1); DEK-NUP214","conceptCode":"C82423","definition":"An acute myeloid leukemia associated with t(6;9)(p22.3;q34.1) resulting in DEK-NUP214(CAN) fusion protein expression. It is often associated with multilineage dysplasia and basophilia. It affects both children and adults and it usually has an unfavorable clinical outcome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A20E-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CABF-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with MECOM (EVI1), GATA2 rearrangement","valueDescription":null,"ValueMeaning":{"publicId":"3257032","version":"1","preferredName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM","longName":"3257032","preferredDefinition":"An acute myeloid leukemia associated with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) resulting in the reposition of a distal GATA2 enhancer to activate MECOM expression. It may present de novo or follow a myelodysplastic syndrome. The clinical course is aggressive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM","conceptCode":"C82426","definition":"An acute myeloid leukemia associated with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) resulting in the reposition of a distal GATA2 enhancer to activate MECOM expression. It may present de novo or follow a myelodysplastic syndrome. The clinical course is aggressive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A1E8-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAC0-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with Other MECOM rearrangements","valueDescription":null,"ValueMeaning":{"publicId":"14673087","version":"1","preferredName":"Acute Myeloid Leukemia with a Variant MECOM Rearrangement","longName":"14673087v1.00","preferredDefinition":"A term referring to acute myeloid leukemias with rearrangement of the MECOM gene with various genes other than the GATA2 gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with a Variant MECOM Rearrangement","conceptCode":"C198846","definition":"A term referring to acute myeloid leukemias with rearrangement of the MECOM gene with various genes other than the GATA2 gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E72D834-CAB9-6F55-E063-731AD00A2921","latestVersionIndicator":"Yes","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAC1-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with RBM15::MRTFA fusion","valueDescription":null,"ValueMeaning":{"publicId":"4358932","version":"1","preferredName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1","longName":"4358932","preferredDefinition":"An acute myeloid leukemia associated with t(1;22)(p13.3;q13.3) resulting in the expression of RBM15-MKL1 fusion protein. It affects infants and children and usually shows megakaryocytic maturation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1","conceptCode":"C82427","definition":"An acute myeloid leukemia associated with t(1;22)(p13.3;q13.1) resulting in the expression of RBM15-MKL1 fusion protein. It affects infants and children and usually shows megakaryocytic maturation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC1DCF52-8398-EF2F-E040-BB89AD435755","latestVersionIndicator":"Yes","beginDate":"2014-06-18","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-06-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAC2-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with RUNX1::RUNX1T1 fusion","valueDescription":null,"ValueMeaning":{"publicId":"4917552","version":"1","preferredName":"Acute Myeloid Leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1","longName":"4917552","preferredDefinition":"An acute myeloid leukemia (AML) showing maturation in the neutrophil lineage.  The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules.  This type of AML is associated with good response to chemotherapy and high complete remission rate.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1","conceptCode":"C9288","definition":"An acute myeloid leukemia with t(8;21)(q22; q22.1) giving rise to RUNX1/RUNX1T1 fusion transcript and showing maturation in the neutrophil lineage. The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules. This type of AML is associated with good response to chemotherapy and high complete remission rate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B7F62E5-D61C-1CE6-E050-BB89AD4312A8","latestVersionIndicator":"Yes","beginDate":"2015-07-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-07-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAC3-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with CBFB::MYH11 fusion","valueDescription":null,"ValueMeaning":{"publicId":"3257038","version":"1","preferredName":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11","longName":"3257038","preferredDefinition":"Acute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality inv(16)(p13.1q22) which results in the expression of the fusion protein CBFB-MYH11.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11","conceptCode":"C9018","definition":"Acute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality inv(16)(p13.1q22) which results in the expression of the fusion protein CBFB-MYH11.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A25A-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAC4-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute promyelocytic leukemia with PML::RARA fusion","valueDescription":null,"ValueMeaning":{"publicId":"4722782","version":"1","preferredName":"Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA","longName":"4722782","preferredDefinition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate.  It is characterized by the t(15;17)(q22;q12) translocation.  There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA","conceptCode":"C3182","definition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate. It is characterized by the PML-RARA fusion. There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-22C4-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAC5-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute promyelocytic leukemia with other RARA fusions","valueDescription":null,"ValueMeaning":{"publicId":"14673088","version":"1","preferredName":"Acute Myeloid Leukemia with a Variant RARA Rearrangement","longName":"14673088v1.00","preferredDefinition":"A term referring to acute myeloid leukemias which show variant translocations involving the RARA gene.  The variant fusion partners include NUMA1, ZBTB16, STAT5B, and NPM1.  These leukemias often have the morphologic features of acute promyelocytic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with a Variant RARA Rearrangement","conceptCode":"C36055","definition":"A term referring to acute myeloid leukemias which show variant translocations involving the RARA gene.  The variant fusion partners include NUMA1, ZBTB16, STAT5B, and NPM1.  These leukemias often have the morphologic features of acute promyelocytic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E72D834-CABA-6F55-E063-731AD00A2921","latestVersionIndicator":"Yes","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAC6-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with BCR::ABL1 fusion","valueDescription":null,"ValueMeaning":{"publicId":"5578258","version":"1","preferredName":"Acute Myeloid Leukemia with BCR-ABL1","longName":"5578258","preferredDefinition":"A rare, de novo acute myeloid leukemia in which the blasts harbor BCR-ABL1 translocation in the absence of a history and clinical and laboratory features of chronic myelogenous leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with BCR-ABL1","conceptCode":"C129785","definition":"A rare, de novo acute myeloid leukemia in which the blasts harbor BCR-ABL1 translocation in the absence of a history and clinical and laboratory features of chronic myelogenous leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41817DF1-B3CC-6EFE-E053-F662850A0613","latestVersionIndicator":"Yes","beginDate":"2016-11-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAC7-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with NPM1 mutation","valueDescription":null,"ValueMeaning":{"publicId":"3257028","version":"1","preferredName":"Acute Myeloid Leukemia with Mutated NPM1","longName":"3257028","preferredDefinition":"An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with NPM1 Mutation","conceptCode":"C82431","definition":"An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A19C-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAC8-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with CEBPA mutation","valueDescription":null,"ValueMeaning":{"publicId":"5578253","version":"1","preferredName":"Acute Myeloid Leukemia with Biallelic Mutations of CEBPA","longName":"5578253","preferredDefinition":"An acute myeloid leukemia with double mutations of the CEBPA gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Biallelic CEBPA Mutation","conceptCode":"C129782","definition":"An acute myeloid leukemia with double mutations of the CEBPA gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41817DF1-B3A7-6EFE-E053-F662850A0613","latestVersionIndicator":"Yes","beginDate":"2016-11-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAC9-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with myelodysplasia - related","valueDescription":null,"ValueMeaning":{"publicId":"4858059","version":"1","preferredName":"Acute Myeloid Leukemia with Myelodysplasia-Related Changes","longName":"4858059","preferredDefinition":"An acute myeloid leukemia with at least 20% blasts in the bone marrow or blood, and either a previous history of myelodysplastic syndrome, multilineage dysplasia or myelodysplastic syndrome-related cytogenetic abnormalities.  There is no history of prior cytotoxic therapy for an unrelated disorder, and there is absence of the cytogenetic abnormalities that are present in acute myeloid leukemia with recurrent genetic abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia, Myelodysplasia-Related","conceptCode":"C7600","definition":"An acute myeloid leukemia with at least 20% blasts in the bone marrow or blood, and either a previous history of myelodysplastic syndrome, multilineage dysplasia or myelodysplastic syndrome-related cytogenetic abnormalities.  There is no history of prior cytotoxic therapy for an unrelated disorder, and there is absence of the molecular abnormalities that are present in acute myeloid leukemia with recurrent genetic abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1805D4A1-425D-4FE2-E050-BB89AD435E9B","latestVersionIndicator":"Yes","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CACA-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with NUP98 rearrangement","valueDescription":null,"ValueMeaning":{"publicId":"14673089","version":"1","preferredName":"Acute Myeloid Leukemia with NUP98 Rearrangement","longName":"14673089v1.00","preferredDefinition":"Acute myeloid leukemia characterized by rearrangement of the NUP98 gene with various genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with NUP98 Rearrangement","conceptCode":"C200411","definition":"Acute myeloid leukemia characterized by rearrangement of the NUP98 gene with various genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E72D834-CABB-6F55-E063-731AD00A2921","latestVersionIndicator":"Yes","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CACB-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with mutated TP53","valueDescription":null,"ValueMeaning":{"publicId":"14673090","version":"1","preferredName":"Acute Myeloid Leukemia with Mutated TP53","longName":"14673090v1.00","preferredDefinition":"Acute myeloid leukemia characterized by the presence of TP53 gene mutations. There are 20% or more blasts in bone marrow or peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Mutated TP53","conceptCode":"C198596","definition":"Acute myeloid leukemia characterized by the presence of TP53 gene mutations. There are 20% or more blasts in bone marrow or peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E72D834-CABC-6F55-E063-731AD00A2921","latestVersionIndicator":"Yes","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CACC-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with other defined genetic alterations","valueDescription":null,"ValueMeaning":{"publicId":"2836816","version":"1","preferredName":"Acute Myeloid Leukemia with Recurrent Genetic Abnormalities","longName":"2836816","preferredDefinition":"A group of acute myeloid leukemias (AMLs) characterized by recurrent genetic abnormalities, mainly balanced translocations.  This group of AMLs often has a high rate of complete remission, and favorable prognosis.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Recurrent Genetic Abnormalities","conceptCode":"C7175","definition":"A group of acute myeloid leukemias characterized by recurrent genetic abnormalities, mainly balanced translocations.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-0663-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CACD-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with minimal differentiation","valueDescription":null,"ValueMeaning":{"publicId":"3323203","version":"1","preferredName":"Acute Myeloid Leukemia, Minimally Differentiated","longName":"3323203","preferredDefinition":"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Minimal Differentiation","conceptCode":"C8460","definition":"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-AFF6-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CACE-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia without maturation","valueDescription":null,"ValueMeaning":{"publicId":"3124348","version":"1","preferredName":"Acute myeloblastic leukemia, without maturation","longName":"3124348","preferredDefinition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils.  The patients present with anemia, neutropenia, and thrombocytopenia.  This type of AML usually follows an aggressive clinical course.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia without Maturation","conceptCode":"C3249","definition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C142120-3A06-8731-E040-BB89AD437683","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CACF-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia with maturation","valueDescription":null,"ValueMeaning":{"publicId":"3124347","version":"1","preferredName":"Acute myeloblastic leukemia, with granulocytic maturation","longName":"3124347","preferredDefinition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. Patients often present with anemia, neutropenia, and thrombocytopenia. AML with the t(8;21) is usually AML with maturation. This type of AML frequently responds to aggressive therapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Maturation","conceptCode":"C3250","definition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C142120-39E3-8731-E040-BB89AD437683","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAD0-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myelomonocytic leukemia","valueDescription":null,"ValueMeaning":{"publicId":"2836785","version":"1","preferredName":"Acute Myelomonocytic Leukemia","longName":"2836785","preferredDefinition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myelomonocytic Leukemia","conceptCode":"C7463","definition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-6815-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAD1-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute monocytic leukemia","valueDescription":null,"ValueMeaning":{"publicId":"2590752","version":"1","preferredName":"Acute Monocytic Leukemia","longName":"2590752","preferredDefinition":"An acute myeloid leukemia in which the majority of monocytic cells are promonocytes.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Monocytic Leukemia","conceptCode":"C4861","definition":"An acute myeloid leukemia in which the majority of monocytic cells are promonocytes.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F3CBD2-0456-469E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAD2-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute erythroid leukemia","valueDescription":null,"ValueMeaning":{"publicId":"3124343","version":"1","preferredName":"Acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b)","longName":"3124343","preferredDefinition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia.  Severe anemia is a common symptom.  This leukemia usually follows an aggressive clinical course.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Erythroid Leukemia","conceptCode":"C8923","definition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C142120-3957-8731-E040-BB89AD437683","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAD3-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute megakaryoblastic leukemia","valueDescription":null,"ValueMeaning":{"publicId":"2836783","version":"1","preferredName":"Acute Megakaryoblastic Leukemia","longName":"2836783","preferredDefinition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Megakaryoblastic Leukemia","conceptCode":"C3170","definition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-67CE-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAD4-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Myeloid sarcoma","valueDescription":null,"ValueMeaning":{"publicId":"2836806","version":"1","preferredName":"Myeloid Sarcoma","longName":"2836806","preferredDefinition":"A tumor mass composed of myeloblasts or immature myeloid cells.  It occurs in extramedullary sites or the bone.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid Sarcoma","conceptCode":"C3520","definition":"A tumor mass composed of myeloblasts or immature myeloid cells.  It occurs in extramedullary sites or the bone.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6246291A-4BBC-4EA6-E040-BB89AD432443","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAD5-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Acute myeloid leukemia, not otherwise specified","valueDescription":null,"ValueMeaning":{"publicId":"4917551","version":"1","preferredName":"Acute Myeloid Leukemia Not Otherwise Specified","longName":"4917551","preferredDefinition":"Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related.  This category includes entities classified according to the French-American-British classification scheme.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia Not Otherwise Specified","conceptCode":"C27753","definition":"Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related.  This category includes entities classified according to the French-American-British classification scheme.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B7F62E5-D5E5-1CE6-E050-BB89AD4312A8","latestVersionIndicator":"Yes","beginDate":"2015-07-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-07-22","modifiedBy":"KUMMEROA","dateModified":"2023-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E72D834-CAD6-6F55-E063-731AD00A2921","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2486813","version":"1","preferredName":"Acute Myeloid Leukemia Type","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003:Type; a subdivision of a particular kind of thing.","longName":"C3171:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"16358911-6379-2575-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-14","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-14","modifiedBy":"ONEDATA","dateModified":"2006-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT MOD","registrationStatus":"Application","id":"0E6F9898-4B71-3938-E063-731AD00AD0B3","latestVersionIndicator":"Yes","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964924","version":"1","longName":"2400r1: Pre-TED","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"TDIS_AML_aml_class","type":"NMDP_FN","context":"NHLBI"},{"name":"PreTed_prime_dis_hct_aml_class","type":"NMDP_FN","context":"NHLBI"},{"name":"CPRE_ICT_aml_class","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:value","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify the AML classification","type":"Application Standard Question Text","description":"Specify the AML classification","url":null,"context":"NHLBI"},{"name":"PQT","type":"Preferred Question Text","description":"What was the classification of the acute myelogenous leukemia?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2682630","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.value(ANY=>CD).translation(CD).code WHERE PerformedDiagnosis.value(ANY=>CD).code = \"Acute Myelogenous Leukemia(AML)\" OR \"acute nonlymphocytic leukemia\" AND PerformedDiagnosis.value(ANY=>CD).translation(CD).codeSystem = \"WHO classification\"","url":null,"context":"NHLBI"},{"name":"Specify the AML classification","type":"Alternate Question Text","description":"Specify the AML classification","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT MOD","registrationStatus":"Application","id":"0E72F4CB-6138-747D-E063-731AD00A9659","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}